Agensys, Inc., a subsidiary of Astellas, has appointed Frank P. Hudson as vice president of finance, and Wolfgang Noe, Ph.D., has been named vice president of process sciences and manufacturing. Agensys, based in Santa Monica, CA, is Astellas’ center of antibody product discovery and development operations.

Mr. Hudson has more than 20 years of experience in the pharmaceutical industry. He joins the company from the Mannkind Corp., where he served as vice president of finance since 2007 and headed fiscal management for R&D operations from genetics research through clinical development. He also has extensive experience within commercial operations and business development.

Dr. Noe joins the company from Biogen Idec, where he most recently served as vice president of strategic development and technical alliances. He began his career with Boehringer Ingelheim in Germany and continued with Biogen Idec as vice president of bioprocess development for seven years and then vice president of strategic alliances and technical development. At Agensys, Dr. Noe will be responsible for manufacturing development and manufacturing of clinical and preclinical drug supplies.

“Frank and Wolfgang each bring a wealth of experience from the biopharma industry to their respective positions,” said Sef Kurstjens, M.D., Ph.D., president and chief executive officer of Agensys. “Frank’s experience in R&D finance is exactly what we were looking for in our candidates, and Wolfgang’s record in preclinical and clinical drug development brings additional strength to our operations. We are looking forward to their contributions at Agensys.”